CBX4 exhibits oncogenic activities in breast cancer via Notch1 signaling

Area of Science:

• Oncology
• Molecular Biology
• Gene Regulation

Background:

• Polycomb chromobox (CBX) proteins, including CBX4, are involved in gene silencing via the polycomb repressive complex (PRC1).
• CBX4's specific role and clinical significance in breast cancer progression are not well-defined.

Purpose of the Study:

• To investigate the role of CBX4 in breast cancer.
• To elucidate the molecular mechanisms underlying CBX4's function in breast cancer.
• To evaluate CBX4 as a potential prognostic biomarker and therapeutic target.

Main Methods:

• Analysis of CBX4 expression in breast cancer tissues and correlation with clinical parameters.
• In vitro studies involving CBX4 overexpression and knockdown to assess effects on cell growth and migration.
• Investigation of the regulatory relationship between CBX4, miR-137, and the Notch1 signaling pathway using promoter activity assays, miRNA target validation, and gene silencing/overexpression experiments.

Main Results:

• CBX4 expression is significantly upregulated in breast cancer tissues and correlates with tumor metastasis, advanced stage, and poor survival.
• CBX4 overexpression enhances breast cancer cell growth and migration, while knockdown inhibits these processes.
• CBX4 suppresses miR-137 expression in a PRC1-dependent manner; miR-137 targets and downregulates Notch1, Jag1, and Hey2.
• Inhibition of Notch1 signaling attenuates CBX4-induced oncogenic phenotypes.

Conclusions:

• CBX4 promotes breast cancer progression by activating the Notch1 signaling pathway through the suppression of miR-137.
• CBX4 serves as a potential prognostic biomarker for breast cancer.
• Targeting the CBX4/miR-137 axis may offer a novel therapeutic strategy for breast cancer treatment.